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BACKGROUND—Telomerase reverse transcriptase (TERT) promoter mutations that may affect
telomerase activity have recently been described in human malignancies. The purpose of this study
was to investigate the clinical correlates of TERT promoter abnormalities in a large cohort of
patients with diverse cancers.
METHODS—This study analyzed TERT promoter alterations and clinical characteristics of 423
consecutive patients for whom molecular testing by next-generation sequencing was performed
between August 2014 and July 2015.
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RESULTS—Of the 423 patients, 61 (14.4%) had TERT promoter mutations, and this placed
TERT promoter alterations among the most prevalent aberrations after tumor protein 53 (TP53;
39%) and KRAS and cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) alterations (15%
each) in this population. TERT promoter alterations were more frequent in men (P=.031) and were
associated with brain cancers (P=.001), skin cancers/melanoma (P=.001), and a higher number of
aberrations (P=.0001). A co-alteration analysis found that TERT promoter alterations were
significantly correlated with CDKN2A/B (P=.001) and BRAF abnormalities (P=.0003). Patients
harboring TERT promoter alterations or TP53 or CDKN2A/B alterations and those with 4 or more
alterations demonstrated shorter survival (hazard ratio for normal TERT promoters vs aberrant
ones, 0.44; P=.017). However, only a higher number of alterations remained significant in the
multivariate analysis.
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CONCLUSIONS—Overall, TERT promoter alterations were among the most prevalent
aberrations in this population, with very high rates in brain cancers (48% of patients) and
melanomas (56% of patients). These aberrations frequently coexist with a high number of other
aberrations, with the latter feature also significantly associated with poorer overall survival.
Therapeutic options for targeting tumors with TERT promoter mutations are currently limited,
although a variety of novel approaches are under development.
Keywords

BRAF; glioblastoma; melanomas; next-generation sequencing; survival; telomerase reverse
transcriptase (TERT) promoter mutations
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Cancer is driven by molecular aberrations allowing oncogenic cells to thrive by growing and
eventually metastasizing. Research studies investigating oncogenic mechanisms have
highlighted the strategies that cancer cells can develop to survive by manipulating pathways
conferring a selective growth advantage to the tumor. Examples of such acquired
mechanisms include sustaining proliferative signaling, evading growth suppressors, resisting
cell death, inducing angiogenesis, activating invasion and metastasis, and enabling
replicative immortality.1 Indeed, in addition to the accumulation of mutations conferring a
selective growth advantage, malignant cells can acquire aberrations leading to immortality.
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In 1995, Chadeneau et al2 demonstrated that telomerase, the enzyme that elongates
telomeric DNA, was present in human cells immortalized in vitro and in metastatic ovarian
and colorectal carcinomas but not in normal tissue. Telomeres are present at the ends of
eukaryotic chromosomes and are composed of simple, repetitive G-rich sequences.
Telomerase reverse transcriptase (TERT) is a catalytic subunit of the telomerase enzyme
responsible for catalyzing the addition of nucleotides to the end of a chromosome’s
telomeres.3 In normal cells, the shortening of telomeres has the ability to activate the
senescence pathway, or the loss of a cell’s power of division and growth.4,5 In parallel, it has
been demonstrated that telomere length stabilization by telomerase would allow unlimited
proliferation.3 It has, therefore, been hypothesized that telomeres hold an important key to
both aging and cancer.6
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Reactivation or re-expression of telomerase is believed to be a widespread feature of human
cancers, although its genetic basis remains poorly understood.7 Although it appears that
somatic mutations in the coding region of TERT are rather infrequent in cancer, somatic
mutations in the TERT promoter region have been described in several specific types of
human cancers (eg, glioblastoma, bladder cancer, thyroid cancer, and skin cancer), and they
lead to increased telomerase expression.8,9 Mutations within the promoter region of TERT
that confer enhanced TERT promoter activity have been reported in 2 major hotspots, which
are located at –124 and –146 base pairs upstream of the transcriptional start site (also
designated C228T and C250T, respectively).8,10,11 Interestingly, mutations in the TERT
promoter region, as opposed to the coding region, allow the creation of additional binding
sites for transcription factors and may represent a novel mechanism of oncogenic activation
in cancer.
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Our study objectives were to investigate the frequency of TERT promoter mutations in our
population of patients with diverse cancer types and to delineate correlations with other
clinical parameters.

MATERIALS AND METHODS
Patients
We retrospectively reviewed the characteristics and clinical outcomes of 423 consecutive
patients for whom molecular testing had been performed between August 2014 and July
2015 and who had been seen at the Moores Cancer Center (University of California San
Diego). This study was performed and consent was obtained in accordance with the
institutional review board guidelines of the University of California San Diego.
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Next-Generation Sequencing
Next-generation sequencing was performed with Foundatio-nOne (Foundation Medicine,
Cambridge, Massachusetts), which is a Clinical Laboratory Improvement Amendments–
approved clinical-grade next-generation sequencing test that interrogates 315 cancer-related
genes plus introns from 28 genes often rearranged or altered in cancer to a typical median
depth of coverage greater than 500 × (the full list is available at http://
www.foundationone.com/learn.php#2). This test can detect base substitutions, insertions and
deletions, copy number alterations, and rearrangements from a routine tissue sample
(including core or fine-needle biopsies).
Statistical Analysis
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Patients’ baseline characteristics were presented with descriptive statistics. Associations
between categorical variables were evaluated with Fisher’s exact test, whereas association
testing for continuous dependent variables used the Mann-Whitney test. Multiple logistic
regressions (multivariate analysis) were fit to analyze the association between TERT
promoter mutations and other patient characteristics. Overall survival was defined as the
time from diagnosis to death or the last follow-up date for patients who were alive. Patients
still alive at the last follow-up were censored at that date. Estimations for overall survival
were performed with a Kaplan-Meier analysis and were compared among subgroups by the
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log-rank test. The Cox regression model was fit to assess the association between overall
survival and multiple other patient characteristics (covariables). Unless otherwise specified,
only variables with P values ≤ .05 were included in the multivariate models. All statistical
analyses were performed by one of the authors (Maria Schwaederle) with SPSS version
22.0.

RESULTS
Patient Characteristics

Author Manuscript

The medical records of 423 consecutive patients who were seen at the Moores Cancer
Center (University of California San Diego) and had comprehensive molecular testing
performed were reviewed and analyzed. There was a slight preponderance of women over
men (54% vs 46%). The median age at diagnosis was 57.2 years (95% confidence interval,
55.1–58.5 years). The majority of our patients were white (69%); the next most common
ethnicity was Asian (10.4%). The most common primary tumor sites were gastrointestinal
(30.3%); they were followed by hematologic malignancies (11.6%), breast cancer (10.9%),
brain cancer (10.4%), lung cancer (10.2%), and skin cancer/melanoma (8%). The median
number of alterations per patient was 4.0 (range, 0–22; Table 1).
TERT Promoter Alterations and Correlation Analysis
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In the overall population, 61 patients (14.4%) had a TERT promoter mutation, and this
placed TERT promoter alterations among the most prevalent aberrations after tumor protein
53 alterations (TP53; 39%) and KRAS and cyclin-dependent kinase inhibitor 2A/B
(CDKN2A/B) alterations (15% each) in our population including diverse cancer types (Fig.
1A). Forty-three of 61 patients (70.5%) carried TERT promoter –124 C>T alterations, 14
patients (23%) carried 146 C>T alterations, and 4 patients (6.6%) carried 124–125 CC>TT
or 138–139 CC>TT alterations (2 patients each).
In a univariate analysis, TERT promoter alterations were found more often in men (21.5%)
than women (8.3%), and they were associated with brain (P <.0001), skin/melanoma (P <.
0001), and head and neck tumors (P =.045). On the other hand, TERT promoter alterations
were significantly less commonly observed in gastrointestinal, hematologic, breast, and lung
cancers. Interestingly, TERT promoter alterations were significantly associated with an
increased median number of alterations (5 vs 3; P <.0001; Table 1). We also observed a
trend toward an association with an older median age at diagnosis (59.1 vs 56.7 years; P =.
060).
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To consider potential confounders, we consecutively performed a multivariate analysis,
which confirmed that TERT promoter alterations correlated with men (P =.031), brain
cancers (P =.001), skin cancer/melanoma (P =.001), and a higher number of aberrations (P
=.0001; Table 2). Indeed, TERT promoter alterations were the most frequent alterations
detected in patients with brain cancers (48% of whom harbored these alterations), and they
were followed by TP53 alterations (34%) and phosphatase and tensin homolog (PTEN)
abnormalities (30%; Fig. 1B). Similarly, 56% of patients with a skin/melanoma malignancy
carried a TERT promoter mutation, and this made the gene the most frequently altered, with
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TP53 (38%) and CDKN2A/B alterations being in the second and third positions,
respectively (Fig. 1C). Even though it was just a trend in the multivariate analysis (P =.184),
it is worth mentioning that 29% of the patients with head and neck cancers harbored a TERT
promoter mutation (Fig. 1D).
For 2 patients with ependymoma, TERT promoter mutations were observed as single
alterations, and the patients were still alive after being diagnosed in 2001 and 2003,
respectively.
Co-Alteration Analysis
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We next investigated the possible associations of TERT promoter alterations with other
alterations, and we found that TERT promoter alterations were significantly associated with
CDKN2A/B, PTEN, neurofibromin 1 (NF1), and BRAF alterations in a univariate analysis
(all P values ≤.004; Table 3). Once adjustments were made for potential confounding
variables in a multivariate analysis including brain and skin/melanoma primary tumor sites,
only CDKN2A/B (P =.001) and BRAF alterations (P =.0003) remained independently
associated with TERT promoter alterations.
When we focused only on patients with brain tumors (n =44), TERT promoter alterations
were associated with epidermal growth factor receptor (EGFR) alterations (33% vs 4.3%; P
=.019), CDKN2A/B alterations (43% vs 4.3%; P =.003), and PTEN alterations (48% vs
13%; P =.020). Although it was not statistically significant, the co-occurrence of TERT
promoter alterations was less frequent in patients with TP53 alterations (19% vs 34%; P =.
060). However, none of these associations remained statistically significant in the multiple
logistic regression model including the alterations with P <.1 in the univariate analysis.
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In patients with skin/melanoma tumors (n =34), we could detect an association between
TERT promoter alterations and BRAF alterations (37% vs 7%) in the multivariate model
including the alterations with P <.1 in the univariate analysis.
Overall Survival
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A log-rank test (univariate) highlighted significantly shorter overall survival for patients
harboring TERT promoter alterations in the overall population (P =.01) as well as TP53 or
CDKN2A/B alterations. In addition, patients with 4 or more alterations (4 alterations being
the median in the overall population) also demonstrated significantly shorter overall survival.
The median overall survival from diagnosis was still not reached at the time of our analysis
(median follow-up, 27.3 months). In the Cox regression model (multivariate analysis), only
4 or more alterations remained an independent prognostic factor associated with shorter
survival (Table 4). Interestingly, subanalyses of the 3 tumor types with the highest
prevalence of TERT alterations demonstrated consistently shorter survival (or a trend toward
shorter survival) for patients with altered TERT promoters in brain tumors (n =44; P =.037),
head and neck cancers (n =28; P =.2), or melanoma/skin tumors (n =34; P =.15).
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DISCUSSION
The TERT gene encodes the reverse transcriptase component of the telomerase complex,
which is necessary for telomere stabilization and cell immortalization. Recently, TERT
promoter mutations have been reported in human malignancies; they create de novo ETS1binding motifs upregulating TERT messenger RNA and telomerase activity in malignant
cells.8,10,13,14
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In our study population, 61 patients (14.4%) had a TERT promoter mutation, and this placed
TERT promoter alterations among the most prevalent aberrations after TP53 (39%). In the
multivariate analysis, TERT promoter alterations were more frequent in men (21.5% of men
and 8.3% of women had an alteration; P =.031) and were associated with brain tumors (48%
of patients; P =.001) and skin cancer/melanoma (56% of patients; P =.001; Table 2). In
previous studies, TERT promoter mutations were found to be the most common point
mutations in several tumor types, including glioblastoma (83%),15 melanoma (71%),10,11
bladder cancer (66%),16 and hepatocellular carcinoma (47%).17 Interestingly, in a recent
study investigating the mutational landscape of metastatic cancer in an extensive cohort
(10,000 patients), Zehir et al18 found a very similar frequency of TERT alterations in their
population covering different tumor types (approximately 15%). In our study, there was also
a trend toward an association with older patients in the univariate analysis but not in the
multivariate analysis. The latter is consistent with other studies in which there has been an
association between TERT promoter alterations and increased age.8,15,19

Author Manuscript
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In univariate analyses, survival was significantly shorter for patients harboring TERT
promoter alterations in the overall population (P =.017) and also for patients with brain
tumors (P =.037; Fig. 2A). Although it did not reach statistical significance, perhaps because
of the limited number of patients, we also observed a trend toward shorter survival in
individuals with melanoma and head and neck tumors (Fig. 2B,C). Similarly, Zehir et al18
described poorer survival with several tumor types for patients harboring TERT promoter
alterations (cutaneous melanoma, papillary thyroid cancer, and bladder urothelial
carcinoma); however, it was statistically significant in the univariate analysis only for
bladder urothelial carcinoma. In addition, the presence of TERT promoter mutations was
previously associated with decreased overall survival in several other studies examining
thyroid cancer,20 urogenital cancer,21 melanoma,22 laryngeal tumors,23 and glioblastomas.
19,24 However, in our study, only a higher number of alterations was retained as a significant
independent variable correlating with survival in the multivariate analysis. Finally, TERT
promoter mutations were associated with alterations in CDKN2A, and the latter anomalies
have also been associated with a poor prognosis.25,26 TERT promoter alterations were
significantly associated with an increased median number of alterations (5 vs 3; P <.0001) in
our population. These results may be of importance because a larger total number of
aberrations is of prognostic value in several tumor types, with more aberrations predicting
shorter progression-free survival.27–29
In our study, 48% of the patients with brain tumors had the TERT promoter mutation, and
patients with these alterations had shorter survival (Fig. 2A). TERT promoter mutations have
been reported in 55% to 84% of glioblastomas and have been associated with increased
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TERT expression.19,30,31 The prevalence of TERT promoter mutations is lower in pediatric
patients with glioblastomas (approximately 11%).32 In agreement with our findings, in brain
tumors, TERT promoter mutations have been associated with EGFR amplification and
inversely correlated with altered TP53.33 However, these associations were not maintained
in the multivariate analysis. Labussiere et al19 showed that TERT promoter mutations were
an independent factor associated with a poor prognosis in glioblastomas (overall survival,
13.8 vs 18.4 months), as were older age and EGFR amplification. In addition, TERT
promoter mutations were associated with shorter overall survival for patients with primary
glioblastomas in another study (11 vs 20 months [P =.002] and 12 vs 20 months [P =.04] for
C228T and C250T, respectively).34 Recently, a new molecular classification of gliomas
using the TERT promoter mutation status has been reported to be highly predictive for
survival.24
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Overall, 56% of the patients with a skin/melanoma malignancy carried a TERT promoter
mutation in our analysis. The –146 C>T mutation is the previously reported most frequently
detected somatic base change in the TERT promoter.8,10 In our skin cancer/melanoma
population (as in our overall cancer population), –124 C>T was the most frequent somatic
base change, with 8 of 19 TERT promoter–altered skin/melanoma tumors (42%) harboring
this specific base change, whereas only 6 patients (31.6%) had a –146 C>T base change.
TERT promoter alterations are associated with poorer survival for patients with cutaneous
melanomas.22 In patients with skin/melanoma tumors (n =34), there was an association
between TERT promoter alterations and BRAF alterations (37% vs 7%). There was only 1
melanoma patient with a concurrent non–BRAF V600 mutation (a BRAF G466E mutation).
Macerola et al35 showed the association between TERT promoter and BRAF mutations to be
an independent poor prognostic factor. Vinagre et al8 also demonstrated that TERT
messenger RNA levels are higher when TERT promoter and BRAF mutations coexist in
melanomas. There is some evidence that BRAF mutations coexisting with TERT promoter
mutations are associated with aggressive behavior in papillary thyroid cancers.36
Interestingly, 29% of the patients with head and neck cancers in our cohort had the TERT
promoter mutation. TERT promoter mutations are predictive of worse survival for patients
with laryngeal cancer.23 In our study population, urothelial cancers accounted for only 3%
of the cancers, with 3 of 13 having a TERT promoter mutation. TERT mutations are frequent
in both noninvasive and invasive bladder tumors.31,37
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Tumor types with high levels of TERT promoter alterations almost always originate in
tissues with relatively low rates of self-renewal (eg, melanomas and gliomas).15 It is
speculated that TERT promoter mutations in these cancers maintain telomerase at levels that
may lead to immortalization or at least prolong shortening of telomere length and
senescence.38,39 This may explain the observed lack of TERT promoter mutations in
gastrointestinal cancers (that continually self-renew) other than hepatocellular cancer.15,17
Our study has some limitations. Most of our analysis evaluated patients with diverse cancers,
although it is possible that this suggests generalizability of the observations across tumor
types. Several subanalyses were performed in specific tumor types; the smaller number of
patients in these subanalyses may have diminished the statistical power. For some other
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cancer types of interest such as those in the bladder, there were only a small number of
patient specimens available, and statistical analysis in this subgroup was not feasible.
Therapeutic options for targeting tumors with TERT promoter mutations are currently
limited, although a variety of treatment approaches to affecting TERT are under
development, including immunotherapies that use TERT as a tumor-associated antigen.40
Common aberrations that coexist with TERT promoter mutations include BRAF and
CDKN2A/B anomalies. Further work is needed to ascertain the responses to BRAF
inhibitors in the presence of coexisting TERT promoter mutations. TERT promoter
mutations lead to increased telomerase activity, which can be targeted with inhibitors.41,42 In
addition, the transcription factor GABPA/B can bind to and activate the TERT promoter.43
Therefore, combinations of experimental drugs that target this pathway and coexisting
molecular aberrations can also be explored.
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In conclusion, abnormalities in the TERT promoter are frequent across diverse cancers, with
14.4% of our patients harboring these aberrations; this makes aberrations in the TERT
promoter among the most prevalent aberrations after TP53 (39% of patients) and KRAS and
CDKN2A/B alterations (15% each) in our population. TERT promoter alterations were more
frequent in men and were associated with brain, skin/melanoma, and head and neck tumors.
Conversely, TERT promoter alterations were significantly less commonly observed in
gastrointestinal, hematologic, breast, and lung cancers. TERT promoter mutations were
associated with higher numbers of alterations, and this feature correlated with poorer
survival. Targeting TERT and telomerase should be a goal of future studies.
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Figure 1.

Author Manuscript

Gene alteration frequencies. The bar graphs show the frequencies of the most common genes
in the most represented tumor types. Only TERT promoter alterations have been tested and
included. (A) Genes with 20 or more patients carrying the alteration are shown. (B–D)
Genes with 5 or more patients carrying the alteration are shown. APC indicates adenomatous
polyposis coli; ARID, AT-rich interaction domain; CDK4, cyclin-dependent kinase 4;
CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; EGFR, epidermal growth factor
receptor; MLL2, mixed-lineage leukemia 2; NF1, neurofibromin 1; NOTCH1, notch
homolog 1; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α;
PTEN, phosphatase and tensin homolog; TERT, telomerase reverse transcriptase; TP53,
tumor protein 53.
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Figure 2.

Kaplan-Meier curves for (A) brain tumors, (B) head and neck cancers, and (C) skin/
melanoma tumors from the date of diagnosis. The log-rank test was used to compare
variables. TERT indicates telomerase reverse transcriptase.
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TABLE 1

Author Manuscript

Patient Characteristics

Characteristic
Age at diagnosis, median (95%
CI), y

Total Patients (n =423
[100%])

TERT Promoter
Alterations (n =61
[14.4%])

TERT Promoter Wild
Type (n =362 [85.6%])

P (Univariate)a

57.2 (55.1–58.5)

59.1 (55.9–62.5)

56.7 (54.7–58.4)

.060

Sex, No. (%)

.0001

Women

228 (53.9)

19 (8.3)

209 (91.7)

Men

195 (46.1)

42 (21.5)

153 (78.5)

White

293 (69.3)

49 (16.7)

244 (83.3)

.051

Asian

44 (10.4)

3 (6.8)

41 (93.2)

.173

Other

39 (9.2)

2 (5.2)

37 (94.8)

—

African American

20 (4.7)

3 (15.0)

17 (85.0)

—

Hispanic

20 (4.7)

4 (20.0)

16 (80.0)

—

Unknown

7 (1.7)

0 (0)

7 (100)

—

Gastrointestinal

128 (30.3)

8 (6.3)

120 (93.7)

.001

Hematologic

49 (11.6)

0 (0)

49 (100)

.0004

Breast

46 (10.9)

0 (0)

46 (100)

.001

Brain

44 (10.4)

21 (47.7)

23 (52.3)

<.0001

Lung

43 (10.2)

0 (0)

43 (100)

.002

Skin/melanoma

34 (8.0)

19 (55.9)

15 (44.1)

<.0001

Head and neck

28 (6.6)

8 (28.6)

20 (71.4)

.045

Otherb

21 (5.0)

1 (4.8)

20 (95.2)

.336

Gynecologic

17 (4.0)

1 (5.9)

16 (94.1)

.487

Genitourinary

13 (3.1)

3 (23.1)

10 (76.9)

.413

4 (3–4)

5 (5–6)

3 (3–4)

<.0001

Ethnicity, No. (%)

Author Manuscript

Type of cancer, No. (%)

Author Manuscript

No. of alterations, median (95%
CI)
Biopsy site used for testing, No.
(%)c

.358

Primary

251 (59.6)

41 (16.3)

210 (83.7)

Metastatic

170 (40.4)

20 (11.8)

150 (88.2)

Abbreviation: CI, confidence interval; TERT, telomerase reverse transcriptase.
Percentages in the Total Patients column are based on the total number of patients (n =423); percentages in the next 2 columns are based on the
numbers in the Total Patients columns. Bolded values are significant.

a

Author Manuscript

Fisher’s exact test was used for categorical variables, and Mann-Whitney tests were used for linear variables (age at diagnostic and number of
alterations). For ethnicity, P values were calculated for the 2 most common ethnicities.

b

Other includes the following: sarcomas (n =6), fibromatosis (n =2), neurofibromas (n =2), neuroendocrine tumors (n =2), and unknown primaries

(n =9).

c
All were tested with the FoundationOne assay; the biopsy site was unknown for 2 patients.
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TABLE 2

Author Manuscript

Multivariate Analysis of Characteristics Associated With TERT Promoter Alterations
TERT Promoter Alterations (n =61
[14.4%])

TERT Promoter Wild Type (n
=362 [85.6%])

Women (n =228)

19 (8.3)

209 (57.7)

Men (n =195)

42 (21.5)

153 (42.3)

8 (6.3)
0 (0)

Characteristic

Wald Statistic

Pa

4.67

.031

120 (93.7)

1.51

.219

49 (100)

0

.997

Sex, No. (%)

Type of cancer, No. (%)
Gastrointestinal (n =128)
Hematologic (n =49)
Breast (n =46)

0 (0)

46 (100)

0

.997

Brain (n =44)b

21 (47.7)

23 (52.3)

11.8

.001

0 (0)

43 (100)

0

.997

Skin/melanoma (n =34)

19 (55.9)

15 (44.1)

10.5

.001

Head and neck (n =28)

8 (28.5)

20 (71.5)

1.8

.184

5 (5–6)

3 (3–4)

14.5

.0001

Lung (n =43)

Author Manuscript

No. of alterations, median (95% CI)

Abbreviation: CI, confidence interval; TERT, telomerase reverse transcriptase.
All percentages are based on the total number of patients with the variable. Bolded values are significant.

a

A logistic regression model was used. Variables with P <.05 in the univariate model (Table 1) were included in the multivariate model. The Wald
test is a way of testing the significance of variables in a statistical model; the higher the Wald statistic is, the higher the association is in the model.

b

Mainly glioblastomas.
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5.0
Overall TERT Promoter Wild Type, %

14.8
19.7

Overall TERT Promoter Alterations, %

NF1

BRAF

31.1

Skin/melanoma

4.1

6.4

4.7

6.4

<.0001

<.0001

Pa

.0001

.004

.001

<.0001

Pa

34.7

39.8

Wald Statistic

13.0

1.4

1.6

12.1

<.0001

<.0001

Pb

.0003

.235

.205

.001

Pb

A multiple logistic regression model was used. The Wald test is a way of testing the significance of variables in a statistical model; the higher the Wald statistic is, the higher the association is in the model.

b

Fisher’s exact test was used. Only genes altered in 25 or more patients (n =13) were tested in the univariate analysis. Bonferroni’s correction12 was used to adjust for multiple testing to select variables to
be included in the subsequent multivariate analysis. Because 13 genes were tested, the adjusted significance level chosen was .004 (0.05/13). Therefore, only genes with a P value ≤ .004 in the univariate
analysis were selected for inclusion in the multiple logistic regression model and were included in this table.

a

Alterations and tumor sites are expressed as percentages of TERT promoter alteration–positive patients and TERT promoter wild-type patients (eg, 34.4% of the overall TERT promoter alterations were in
brain tumors). Bolded values are significant.

Abbreviation: CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; NF1, neurofibromin 1; PTEN, phosphatase and tensin homolog; TERT, telomerase reverse transcriptase.

34.4

Brain

Tumor Site

19.7

PTEN

11.0

39.3

CDKN2A/B

TERT Promoter Wild Type (n =362), %

TERT Promoter Alterations (n =61), %

Alteration

Wald Statistic

Author Manuscript

Co-Alterations in the Presence of TERT Promoter Anomalies (Multivariate Analysis)

Author Manuscript
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TABLE 4

Author Manuscript

Overall Survival Analysis: Univariate and Multivariate Correlates
Univariate
Variable

HR (95% CI)

Multivariate
Pa

HR (95% CI)

Pb

Alterationsc

TERT promoter

0.441 (0.22–0.88)

.017

0.635 (0.31–1.31)

.220

TP53

0.506 (0.27–0.94)

.027

0.637 (0.33–1.23)

.179

CDKN2A/B

0.404 (0.20–0.80)

.008

0.613 (0.29–1.31)

.207

0.242 (0.11–0.53)

.0001

0.337 (0.15–0.78)

.012

No. of alterations ≥ 4

Abbreviations: CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; CI, confidence interval; HR, hazard ratio; TERT, telomerase reverse
transcriptase; TP53, tumor protein 53.
The bolded value is significant.

Author Manuscript

a

The log-rank test was used. Only significant variables are represented in the univariate analysis.

b

A Cox regression model was used. The median overall survival was not reached at the time of this analysis. The median follow-up time from
diagnosis was 27.3 months (95% CI, 23.2–31.4 months).

c

Patients with alterations in the TERT promoter, TP53, or CDKN2A/B did worse than those without alterations; patients with 4 or more alterations
did worse than those with fewer alterations.
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